English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe University of Texas MD Anderson Cancer Center today announced Kimberly Hoggatt Krumwiede, Ph.D., as dean of MD Anderson’s School of Health Professions (SHP), effective Aug. 1.
Tag: MD Anderson Cancer Center
MD Anderson and Turning Point Therapeutics announce strategic alliance to advance precision cancer therapies
MD Anderson and Turning Point Therapeutics announced a strategic research and development alliance to evaluate Turning Points investigational targeted therapies against ROS1, NTRK, MET and other cancer drivers.
Estimating tumor-specific total mRNA level predicts cancer outcomes
Researchers have developed a mathematical tool to estimate tumor-specific RNA levels from tumor samples with mixed cell types. Using this technique on thousands of samples found that higher mRNA levels are correlated with shorter survival.
Genetic study offers new insights into DCIS biology, progression
A new genetic study discovered that not all breast cancers that develop after DCIS arise from the original DCIS lesion. Roughly 1 in 5 are new cancers, genetically unrelated to the original DCIS.
MD Anderson researchers present cellular therapy advances at the 2022 ASCO Annual Meeting
Promising clinical results with cellular therapies for patients with blood cancers highlight advances being presented by researchers from The University of Texas MD Anderson Cancer Center at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
These findings include long-term outcomes of patients receiving an infusion of brexucabtagene autoleucel (KTE-X19) for mantle cell lymphoma, efficacy of gamma delta CAR T therapy for aggressive B-cell lymphoma and responses of umbilical cord blood-derived expanded natural killer cells when given together with combination therapy before stem cell transplant.
Ibrutinib with chemoimmunotherapy improved progression-free survival for newly diagnosed mantle cell lymphoma patients
Combination chemoimmunotherapy with the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free survival over standard chemoimmunotherapy for previously untreated mantle cell lymphoma (MCL) in patients 65 and over, researchers from The University of Texas MD Anderson Cancer Center reported today at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. The study results also were published today in the New England Journal of Medicine.
MD Anderson and Resilience launch joint venture to accelerate development and manufacturing of innovative cell therapies for cancer
MD Anderson and Resilience today announced the launch of a joint venture, the Cell Therapy Manufacturing Center, which unites the strengths of both parties to accelerate the development and manufacturing of cell therapies for patients with cancer.
MD Anderson Research Highlights: ASCO 2022 Special Edition
This special edition features upcoming oral presentations by MD Anderson researchers at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting focused on quality improvement, health services research, new treatments for skin cancers, and symptoms and survivorship advances. More information on ASCO content from MD Anderson can be found at MDAnderson.org/ASCO.
MD Anderson Research Highlights: SITC 2021 Special Edition
This special edition of MD Anderson’s Research Highlights features presentations at the Society for Immunotherapy of Caner 36th Annual Meeting.
Serial radiation therapy is safe and effective as alternative treatment to systemic therapy for kidney cancer
In a new single-arm study, researchers at The University of Texas MD Anderson Cancer Center reported that radiation therapy as monotherapy is a safe and effective noninvasive treatment for oligometastatic renal cell carcinoma (RCC). The findings were published today in The Lancet Oncology
MD Anderson and Siemens Healthineers collaborating to enable consistent clinical implementation of quantitative MRI
MD Anderson and Siemens Healthineers have announced the collaborative development of an education program focused on enabling the implementation of consistent, high-quality MRI in radiation oncology.
Ribociclib added to endocrine therapy extends survival in postmenopausal patients with metastatic breast cancer
A study led by researchers from The University of Texas MD Anderson Cancer Center showed a significant overall survival benefit with ribociclib plus endocrine therapy for postmenopausal patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. This is the first demonstration of a survival advantage with a front-line CDK4/6 inhibitor in postmenopausal patients with
HR+/HER 2- advanced breast cancer.
MD Anderson Research Highlights: ESMO 2021 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent studies in basic, translational and clinical cancer research from MD Anderson experts. This special edition features oral presentations by MD Anderson researchers at the virtual European Society for Medical Oncology (ESMO) Congress 2021 on novel therapeutic approaches, including cell therapy for solid tumors, antibody drug conjugates targeting TROP2 and neoadjuvant pembrolizumab for advanced solid tumors with mismatch repair deficiencies.
Link between inflammation and pancreatic cancer development uncovered
A new study in Science finds that pancreatic cells display an adaptive response to repeated inflammation that initially protects against tissue damage but can promote tumor formation in the presence of mutant KRAS.
MD Anderson to pay tribute to legendary Emil J Freireich, M.D., in virtual celebration on Sept. 23
MD Anderson to honor the life of trailblazing oncologist Emil J Freireich, M.D., in a virtual tribute event on Sept. 23
Long-term benefit of SABR for operable early-stage NSCLC shown in new study
A new study from researchers at The University of Texas MD Anderson Cancer Center showed that stereotactic ablative radiotherapy (SABR) was as effective as surgery at providing long-term benefits to patients with operable early-stage non-small cell lung cancer (NSCLC) and generated minimal side effects. The study is the first of its kind to compare long-term results of SABR against surgical treatment in patients with operable early-stage NSCLC.
MD Anderson and SNIPR BIOME collaborate to advance next-generation CRISPR microbiome therapeutics
MD Anderson and SNIPR BIOME have announced a strategic collaboration to advance next-generation CRISPR-based microbiome therapies to reduce immune-related side effects in patients treated with immune checkpoint inhibitors.
MD Anderson and Bellicum Announce Additional License Agreement for Use of CaspaCIDe® Safety Switch
The University of Texas MD Anderson Cancer Center and Bellicum Pharmaceuticals, Inc. today announced a global option and license agreement covering certain intellectual property and technology rights regarding Bellicum’s CaspaCIDe® (inducible caspase-9, or iC9) safety switch and related technologies, and the use of rimiducid, an agent used to activate the safety switch.
Omer Sultan joins MD Anderson as new Chief Financial Officer
Omer Sultan joins MD Anderson as new Chief Financial Officer
Statins may improve survival for triple-negative breast cancer patients
A study led by researchers from The University of Texas MD Anderson Cancer Center found a significant association between cholesterol-lowering drugs commonly known as statins and survival rates of triple-negative breast cancer patients. Since statins are low in cost, easy to access and produce minimal side effects, this could have an important impact on outcomes for this aggressive disease.
MD Anderson hosts virtual Leading Edge of Cancer Research Symposium
MD Anderson hosts the Leading Edge of Cancer Research Symposium on November 4-5, 2021, featuring presentations from distinguished cancer researchers and a virtual poster session, open to all.
MD Anderson and Blueprint Medicines announce strategic collaboration to accelerate BLU-222 development
MD Anderson and Blueprint Medicines announced a three-year strategic collaboration to accelerate the development of BLU-222, an investigational targeted therapy against CDK2.
Atezolizumab and bevacizumab show meaningful responses for malignant peritoneal mesothelioma patients
A phase II study led by researchers from The University of Texas MD Anderson Cancer Center found that treatment with atezolizumab and bevacizumab was well-tolerated and resulted in a 40% objective response rate in patients with advanced malignant peritoneal mesothelioma, a rare cancer in the lining of the abdomen.
MD Anderson and Hummingbird Bioscience announce strategic research collaboration to advance innovative immunotherapies
MD Anderson and Hummingbird Bioscience announced a multi-year strategic research collaboration to investigate HMBD-002, Hummingbird’s VISTA antagonist antibody, as a novel immunotherapy for cancer.
Engineered NK cells can eliminate glioblastoma stem cells
Preclinical research finds that glioblastoma stem cells can be targeted by NK cells, but they are able to evade immune attack by releasing TFG-β. Deleting the TFG-β receptor in NK cells renders them resistant to this and restores their anti-tumor activity.
Combination targeted therapy provides durable remission for patients with chronic lymphocytic leukemia
A combination of ibrutinib and venetoclax was found to provide lasting disease remission in patients with newly diagnosed chronic lymphocytic leukemia (CLL), according to researchers at The University of Texas MD Anderson Cancer Center. Findings from the single-institution Phase II study were published today in JAMA Oncology and provide the longest follow-up data on patients treated with this drug regimen.
Targeted Therapy Pralsetinib Safely and Effectively Treats Lung and Thyroid Cancers with RET Alterations
Results from the multi-cohort Phase I/II ARROW clinical trial, conducted by The University of Texas MD Anderson Cancer Center researchers, showed that a once-daily dose of pralsetinib, a highly selective RET inhibitor, was safe and effective in treating patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC) and RET-altered thyroid cancer.
Glioblastoma study discovers protective role of metabolic enzyme, revealing a novel therapeutic target
MD Anderson researchers have discovered a new role for the metabolic enzyme, MCAD, in glioblastoma. The enzyme prevents toxic fatty acid accumulation, in addition to its normal role in energy production, and targeting MCAD led to irreversible damage and cell death specifically in cancer cells.
New AI-based tool can find rare cell populations in large single-cell datasets
MD Anderson researchers have developed a first-of-its-kind AI tool to identify rare groups of biologically important cells from the noise of large, complex single-cell datasets. The new tool, called SCMER, can help reserachers gain new insights across many applications.
Metabolic inhibitor IACS-6274 shows early antitumor effects in underserved patients with advanced cancers
A metabolic inhibitor drug, IACS-6274, developed by MD Anderson’s Therapeutics Discovery division, is well-tolerated and showed early signs of anti-tumor activity in a Phase I trial being presented at the 2021 ASCO Annual Meeting.
Combination therapy achieves high rates of response for patients with acute lymphoblastic leukemia
A combination of ponatinib and blinatumomab was found to be safe and highly effective in patients with newly diagnosed or relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), according to researchers at The University of Texas MD Anderson Cancer Center. The study may support a regimen to produce complete remission with front-line therapy, without the increased risks associated with systemic chemotherapy or a stem cell transplant.
MD Anderson and Broad Institute launch new translational research platform focused on rare cancers
MD Anderson and the Broad Institute have launched a translational research platform to study rare cancers. The initiative will lead to a first-of-its-kind resource for the scientific community and will help to accelerate new therapies for patients with rare tumor types.
The 8th Annual Joseph Calello Melanoma Scholar, Dr. Charles Balch, to Present “The Surgical Management of Melanoma,” a Virtual Lecture, May 6
Atlantic Health System Cancer Care, in partnership with OncLive, invites health care professionals and others interested in the surgical management of melanoma to a virtual lecture by internationally known melanoma expert Charles M. Balch, MD, FACS, FASCO. Dr. Balch is this year’s Joseph Calello Melanoma Scholar. The free lecture and Q & A will be held on May 6, 11 a.m. – 12 p.m. ET.
Antiviral T cells safe and effective for treating debilitating complication common after stem cell transplants
A Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center found that BK virus (BKV)-specific T cells from healthy donors were safe and effective as an off-the-shelf therapy for BKV-associated hemorrhagic cystitis (BKV-HC), a painful complication common after allogeneic stem cell transplants for patients with leukemia or lymphoma. The study was published today in the Journal of Clinical Oncology.
MD Anderson and Boehringer Ingelheim expand collaboration to accelerate development of KRAS and TRAILR2 compounds in lung cancer
MD Anderson and Boehringer Ingelheim have expanded their joint Virtual Research and Development Center to accelerate the development of new targeted therapies against KRAS and TRAILR2 in lung cancer.
MD Anderson’s Guillermina Lozano elected to Fellows of the AACR Academy
Guillermina (Gigi) Lozano, Ph.D., chair of Genetics at The University of Texas MD Anderson Cancer Center, has been elected to the 2021 class of Fellows of the American Association for Cancer Research (AACR) Academy in recognition of her pioneering work to describe the p53 tumor suppressor pathway, which is undermined in many cancers.
New sequencing approach finds triple-negative breast cancers continue accumulating genetic changes during tumor growth
A new DNA sequencing approach developed by MD Anderson researchers overcomes technical challenges with earlier techniques to give deeper insights into breast cancer evolution.
Collagen plays protective role during pancreatic cancer development
Contrary to long-held beliefs, new research finds that collagen in the tumor microenvironment may not promote cancer development but plays a protective role in controlling pancreatic cancer growth. The new findings could have important therapeutic implications.
MD Anderson and Mirati Therapeutics announce KRAS strategic research and development collaboration in solid tumors
The University of Texas MD Anderson Cancer Center and Mirati Therapeutics, Inc. today announced a strategic research and development collaboration to expand the evaluation of Mirati’s two investigational small molecule, potent and selective KRAS inhibitors – adagrasib (MRTX849), a G12C inhibitor in clinical development, and MRTX1133, a G12D inhibitor in preclinical development, as monotherapy and in combination with other agents – which target two of the most frequent KRAS mutations in cancer.
New computational tool reliably differentiates between cancer and normal cells from single-cell RNA-sequencing data
MD Anderson researchers have developed a new computational tool to accurately differentiate between cancer cells and normal cells when analyzing large single-cell RNA-sequencing data.
Mediterranean diet may decrease risk of prostate cancer progression for men on active surveillance
In a study to examine a Mediterranean diet in relation to prostate cancer progression in men on active surveillance, researchers from The University of Texas MD Anderson Cancer Center found that men with localized prostate cancer who reported a baseline dietary pattern that more closely follows the key principles of a Mediterranean-style diet fared better over the course of their disease.
Combination of chemotherapy and blinatumomab improves survival for patients with B-cell acute lymphoblastic leukemia
A study led by The University of Texas MD Anderson Cancer Center showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab resulted in increased survival and achieved a high rate of measurable residual disease (MRD) negativity for patients who were newly diagnosed with a high-risk form of acute lymphoblastic leukemia (ALL) known as Philadelphia chromosome-negative B-cell ALL (Ph-negative B-ALL).
New targeted therapy blocks metabolism in brain cancer cells with genetic vulnerability
Researchers at The University of Texas MD Anderson Cancer Center have developed a novel targeted therapy, called POMHEX, which blocks critical metabolic pathways in cancer cells with specific genetic defects. Preclinical studies found the small-molecule enolase inhibitor to be effective in killing brain cancer cells that were missing ENO1, one of two genes encoding the enolase enzyme.
A Conversation With a Living Legend honoring Admiral William H. McRaven raises $1 million
The North Texas A Conversation With a Living Legend® raised $1 million this week in a virtual version of the signature fundraising event benefiting The University of Texas
MD Anderson Cancer Center. The 31st annual event honored Admiral William H. McRaven, U.S. Navy, Retired, in an interview Nov. 16 with CBS News’ Bob Schieffer. Proceeds will benefit MD Anderson’s Moon Shots Program®, a collaborative effort to accelerate the development of scientific discoveries into clinical advances that save patients’ lives.
MD Anderson and Obsidian Therapeutics announce strategic collaboration to accelerate advancement of novel engineered tumor infiltrating lymphocyte therapy (cytoTIL™) for solid tumors
The University of Texas MD Anderson Cancer Center and Obsidian Therapeutics, Inc. today announced a multi-year strategic collaboration designed to expedite the research and development of novel engineered tumor infiltrating lymphocytes (TILs) for the treatment of solid tumors. The agreement pairs Obsidian and its novel cytoDRiVE™ technology platform with MD Anderson’s extensive experience and state-of-the-art capabilities in TIL cell therapy, led by the Biologics Development platform, within the Therapeutics Discovery division.
MD Anderson researchers present immunotherapy advances at Society for Immunotherapy of Cancer Annual Meeting
Promising clinical results with combination treatments for patients with melanoma and lung cancer highlight immunotherapy advances being presented by researchers from The University of Texas MD Anderson Cancer Center at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020) .
Ovarian Cancer Screening Study Focuses on Early Detection in Women at Low Risk
Atlantic Health System is enrolling women in a landmark study that uses a simple blood test for the CA-125 protein to screen women who are at low risk for ovarian cancer. The purpose of the clinical trial is to help determine whether this test can catch ovarian cancer early in women who would not normally be screened for it. Atlantic Health System hospitals are the only centers in the New York metro region to participate in the study, and have the third highest enrollment numbers in the nation.
Large-scale cancer proteomics study profiles protein changes in response to drug treatments
Through large-scale profiling of protein changes in response to drug treatments in cancer cell lines, researchers at The University of Texas MD Anderson Cancer Center have generated a valuable resource to aid in predicting drug sensitivity, to understand therapeutic resistance mechanisms and to identify optimal combination treatment strategies.
MD Anderson’s fifth annual Boot Walk to End Cancer® goes virtual Nov. 7
The University of Texas MD Anderson Cancer Center will host the fifth annual Boot Walk to End Cancer® virtually on Saturday, Nov. 7. The virtual walk will take place online and in neighborhoods across the country in an effort to keep participants, their families and their communities safe and as part of MD Anderson’s commitment to prioritizing the health and safety of patients, workforce members and the greater Houston community.
Focus Fund and MD Anderson launch investment fund to support promising investigational cancer therapies in early-stage clinical trials
The Focus Fund GP, LLC, in partnership with The University of Texas MD Anderson Cancer Center, has launched Cancer Focus Fund, LP, an oncology-focused investment fund designed to support the advancement of compelling investigational cancer therapies from late preclinical development through Phase I and Phase Ib/II clinical trials.